Press Release

BioScale, Inc. Named as a 2011 Top 300 Startup by FundedIDEAS

Lexington, MA - BioScale, today announced that it has been named one of  the top 300 startups from more than 2,500 qualifying global companies and is included  in the 2011 Edition of the fundedIDEAS publication  - TOP 300 STARTUPS. BioScale was specifically selected by an eminent panel of business and industry leaders spanning the globe based on 14 parameters including strength of the management team, business model and execution strategy as well as industry and sector outlook. Being chosen as a member of the 2011 TOP 300 STARTUPS demonstrates BioScale’s ongoing commitment to innovation, sustainability and excellence.

“We very much appreciate the recognition by FundedIDEAS, and realize that this award reflects not only the confidence that our investors have in our innovative protein analysis technology but the validation we have received from our key pharmaceutical and biotech customers,” commented Mark Lundstrom, BioScale CEO.  “Our focus is on providing transformative technology to advance cutting-edge science into groundbreaking discoveries.  We look forward to the challenge of establishing a leadership position in the market place”

"We are excited to feature BioScale as a TOP 300 STARTUP," said Jonathon Marcus, Editor with fundedIDEAS. “We are extremely confident of their ability to innovate and adapt to changing market and customer needs, while driving innovation in the proteomics sector."

TOP 300 STARTUPS winners were selected from a pool of 2,518 companies who secured institutional funding in 2010. The fundedIDEAS editorial team conducted a rigorous four-month selection process prior to inclusion.

About BioScale
BioScale is a life science company that develops, manufactures and promotes a proprietary protein analysis technology to accelerate the discovery, development and production of biological and pharmaceutical products. BioScale’s innovative ViBE™ platform powered by its AMMP™ (Acoustic Membrane Microparticle) technology enables highly-sensitive detection and quantitation of proteins in complex samples used in pre-clinical and clinical research, bioprocess, patient point-of-care and personalized medicine applications. BioScale is headquartered in Lexington, MA. For more information, visit www.bioscale.com.
About fundedIDEAS
9 out of 10 startups fail to achieve their stated business objectives. fundedIDEAS was established with the sole objective of discovering the ones that will. Rating each startup on 14 parameters, from strength of the management team, business model and execution strategy to industry and sector outlook – we deploy the most advanced methodology to establish the stability, sustainability and outlook of venture funded startups. To know more, please visit www.fundedIDEAS.com